Silvia Kocova El-Arini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Silvia Kocova El-Arini has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Hans Leuenberger
Industrial Pharmacy Lab, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstr. 50, 4056 Basel, Switzerland
5 shared publicationsN. Pilpel
Department of Pharmacy, Chelsea College of Science, University of London , London SW3 6LX
4 shared publicationsGerald K. Shiu
Biopharmaceutics Research Branch, Division of Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, 200 C Street S.W., Washington, DC 20204 USA
3 shared publicationsŠeherzada Hadžidedić
Bosnalijek d.d., Development Department, Jukićeva 53, 71000 Sarajevo, Bosnia and Herzegovina
3 shared publicationsAhmed Abdelbary
Department of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, Egypt
2 shared publicationsErvina Hadžović
Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
2 shared publications
Latest Publications
- 22 May 2020
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 16 (2) , 384-390
Bioanalytical Comparison of Transdermal Delivery of Tizanidine from Different Nanovesicular Carriers
- 22 May 2020
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 16 (2) , 384-390
Bioanalytical Comparison of Transdermal Delivery of Tizanidine from Different Nanovesicular Carriers
- 8 November 2019
- Published by Taylor & Francis in Journal of Liposome Research
- Vol. 31 (1) , 19-29
Development of tizanidine loaded aspasomes as transdermal delivery system: ex-vivo and in-vivo evaluation
New generation of amphiphilic vesicles known as aspasomes were investigated as potential carriers for transdermal delivery of tizanidine (TZN). Using full factorial design, an optimal formulation was developed by evaluating the effects of selected variables on the properties of the vesicles with regards to entrapment efficiency, vesicle size and cumulative percentage released. The optimal formula (TZN-AS 6) consisting of 20 mg TZN, 50 mg ascorbyl palmitate (AP), 50 mg cholesterol (CH) and 50 mg Span 60, represented well dispersed spherical vesicles in the nanorange sizes and exhibited excellent stability under different storage conditions. Ex-vivo permeation studies using excised rat skin showed a 4.4-fold increase of the steady state flux in comparison to the unformulated drug (p < 0.05). The pharmacokinetic parameters obtained from the in-vivo study using Wistar rats, showed that the bioavailability of TZN was enhanced significantly (p < 0.05) when compared to the oral market product of TZN, Sirdalud®. Moreover, skin irritancy tests confirmed that the vesicles were noninvasive and safe for the skin. Based on the results obtained, the optimized aspasomes formula represents a promising Nano platform for TZN to be administered transdermally, thus improving the therapeutic efficacy of this important muscle relaxant.
- 8 November 2019
- Published by Taylor & Francis in Journal of Liposome Research
- Vol. 31 (1) , 19-29
Development of tizanidine loaded aspasomes as transdermal delivery system: ex-vivo and in-vivo evaluation
New generation of amphiphilic vesicles known as aspasomes were investigated as potential carriers for transdermal delivery of tizanidine (TZN). Using full factorial design, an optimal formulation was developed by evaluating the effects of selected variables on the properties of the vesicles with regards to entrapment efficiency, vesicle size and cumulative percentage released. The optimal formula (TZN-AS 6) consisting of 20 mg TZN, 50 mg ascorbyl palmitate (AP), 50 mg cholesterol (CH) and 50 mg Span 60, represented well dispersed spherical vesicles in the nanorange sizes and exhibited excellent stability under different storage conditions. Ex-vivo permeation studies using excised rat skin showed a 4.4-fold increase of the steady state flux in comparison to the unformulated drug (p < 0.05). The pharmacokinetic parameters obtained from the in-vivo study using Wistar rats, showed that the bioavailability of TZN was enhanced significantly (p < 0.05) when compared to the oral market product of TZN, Sirdalud®. Moreover, skin irritancy tests confirmed that the vesicles were noninvasive and safe for the skin. Based on the results obtained, the optimized aspasomes formula represents a promising Nano platform for TZN to be administered transdermally, thus improving the therapeutic efficacy of this important muscle relaxant.
- 4 October 2013
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 19 (8) , 930-941
The impact of chirality on the development of robust and stable tablet formulation of (S-) amlodipine besylate
The aim of this study was to compare the specific characteristics of the S-enantiomer and the racemate of amlodipine besylate (AB) in order to design a robust and stable formulation of the active S-enantiomer which will guarantee continuous performance of the unichiral version of amlodipine. Preformulation studies showed that the S-enantiomer and the racemate exhibit different crystal morphology, particle size distribution and higroscopicity. The S-enantiomer exhibited significantly lower melting temperature compared to the racemate which was in accordance with its higher water solubility and its increased intrinsic dissolution rate. The thermograms of S-amlodipine besylate indicated that dehydration and melting occur at almost the same time and the dehydration event overlaps with the melting peak. Forced degradation tests conducted on both substances showed high levels of degradation into amlodipine related substance D as well as other impurities. Tablets prepared with S-AB, simulating originator’s formulation, failed in stability tests due to drug incompatibility with calcium hydrogen phosphate. Therefore, a tablet formulation based on excipients which were confirmed compatible with S-AB was developed and optimized using full factorial design to obtain a dissolution profile comparative to the brand product. Stability studies conducted at 40 °C/75% relative humidity (RH) confirmed that appearance, drug content and drug release of the optimized tablet formulation remained within the recommended limits.
- 4 October 2013
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 19 (8) , 930-941
The impact of chirality on the development of robust and stable tablet formulation of (S-) amlodipine besylate
The aim of this study was to compare the specific characteristics of the S-enantiomer and the racemate of amlodipine besylate (AB) in order to design a robust and stable formulation of the active S-enantiomer which will guarantee continuous performance of the unichiral version of amlodipine. Preformulation studies showed that the S-enantiomer and the racemate exhibit different crystal morphology, particle size distribution and higroscopicity. The S-enantiomer exhibited significantly lower melting temperature compared to the racemate which was in accordance with its higher water solubility and its increased intrinsic dissolution rate. The thermograms of S-amlodipine besylate indicated that dehydration and melting occur at almost the same time and the dehydration event overlaps with the melting peak. Forced degradation tests conducted on both substances showed high levels of degradation into amlodipine related substance D as well as other impurities. Tablets prepared with S-AB, simulating originator’s formulation, failed in stability tests due to drug incompatibility with calcium hydrogen phosphate. Therefore, a tablet formulation based on excipients which were confirmed compatible with S-AB was developed and optimized using full factorial design to obtain a dissolution profile comparative to the brand product. Stability studies conducted at 40 °C/75% relative humidity (RH) confirmed that appearance, drug content and drug release of the optimized tablet formulation remained within the recommended limits.
- 15 September 2011
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 416 (1) , 97-103
Investigation of compressibility and compactibility parameters of roller compacted Theophylline and its binary mixtures
- 15 September 2011
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 416 (1) , 97-103
Investigation of compressibility and compactibility parameters of roller compacted Theophylline and its binary mixtures
- 30 August 2010
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 396 (1-2) , 53-62
Roller compaction of different pseudopolymorphic forms of Theophylline: Effect on compressibility and tablet properties
- 30 August 2010
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 396 (1-2) , 53-62
Roller compaction of different pseudopolymorphic forms of Theophylline: Effect on compressibility and tablet properties
- 15 February 2010
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 386 (1-2) , 77-90
Investigation of intrinsic dissolution behavior of different carbamazepine samples
- 15 February 2010
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 386 (1-2) , 77-90
Investigation of intrinsic dissolution behavior of different carbamazepine samples
- 1 January 2010
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 20 (5) , 367-376
Investigation and development of robust process for direct pelletization of lansoprazole in fluidized bed rotary processor using experimental design
- 1 January 2010
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 20 (5) , 367-376
Investigation and development of robust process for direct pelletization of lansoprazole in fluidized bed rotary processor using experimental design
- 8 January 2002
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 7 (3) , 361-371
Evaluation of Disintegration Testing of Different Fast Dissolving Tablets Using the Texture Analyzer
(2002). Evaluation of Disintegration Testing of Different Fast Dissolving Tablets Using the Texture Analyzer. Pharmaceutical Development and Technology: Vol. 7, No. 3, pp. 361-371. doi: 10.1081/PDT-120005732
- 8 January 2002
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 7 (3) , 361-371
Evaluation of Disintegration Testing of Different Fast Dissolving Tablets Using the Texture Analyzer
(2002). Evaluation of Disintegration Testing of Different Fast Dissolving Tablets Using the Texture Analyzer. Pharmaceutical Development and Technology: Vol. 7, No. 3, pp. 361-371. doi: 10.1081/PDT-120005732
- 1 July 1998
- Published by Elsevier in Pharmaceutica Acta Helvetiae
- Vol. 73 (2) , 89-94
Dissolution properties of praziquantel–PVP systems
- 1 July 1998
- Published by Elsevier in Pharmaceutica Acta Helvetiae
- Vol. 73 (2) , 89-94
Dissolution properties of praziquantel–PVP systems
- 1 January 1998
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 3 (4) , 557-564
Solubility Properties of Racemic Praziquantel and Its Enantiomers
The purpose of this study was to characterize the solubility and thermodynamic properties of the optical isomers of the anti-schistosomal drug, praziquantel (PZQ) and to compare these properties to those of the racemic product used in commercial preparations (Biltricide®, generic drugs), The crystalline enantiomers of PZQ exhibited different thermal properties than the racemic drug. The melting points and the enthalpies of fusion obtained from the differential scanning calorimetry (DSC) scans were nearly identical between the isomers and were substantially lower than those of racemic PZQ [(±)-PZQ]. The DSC results indicate that (±)-PZQ is a racemic compound and not a racemic mixture. This was confirmed by powder x-ray diffraction analysis and the IR spectra. The 30° decrease in the melting point was reflected in increased solubility of the enantiomers, which amounted to twice that of the racemic PZQ. The behavior of the isomers in the presence of β-cyclodextrin (β-CD) was studied in water at 37°C. The solubility data (phase solubility diagrams) were linear for up to the highest concentration of added β-CD investigated. The apparent stability constants determined from the phase solubility diagrams showed that both the (+) and (-) enantiomers as well as (&[±)-PZQ exhibited moderate affinity to form a 1:1 complex in solution with β-CD. The findings of this study may be of importance when efforts are considered to improve pharmaceutical formulation of this anti-schistosomal drug.
- 1 January 1998
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 3 (4) , 557-564
Solubility Properties of Racemic Praziquantel and Its Enantiomers
The purpose of this study was to characterize the solubility and thermodynamic properties of the optical isomers of the anti-schistosomal drug, praziquantel (PZQ) and to compare these properties to those of the racemic product used in commercial preparations (Biltricide®, generic drugs), The crystalline enantiomers of PZQ exhibited different thermal properties than the racemic drug. The melting points and the enthalpies of fusion obtained from the differential scanning calorimetry (DSC) scans were nearly identical between the isomers and were substantially lower than those of racemic PZQ [(±)-PZQ]. The DSC results indicate that (±)-PZQ is a racemic compound and not a racemic mixture. This was confirmed by powder x-ray diffraction analysis and the IR spectra. The 30° decrease in the melting point was reflected in increased solubility of the enantiomers, which amounted to twice that of the racemic PZQ. The behavior of the isomers in the presence of β-cyclodextrin (β-CD) was studied in water at 37°C. The solubility data (phase solubility diagrams) were linear for up to the highest concentration of added β-CD investigated. The apparent stability constants determined from the phase solubility diagrams showed that both the (+) and (-) enantiomers as well as (&[±)-PZQ exhibited moderate affinity to form a 1:1 complex in solution with β-CD. The findings of this study may be of importance when efforts are considered to improve pharmaceutical formulation of this anti-schistosomal drug.